Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 8/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 8/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2661245 | 0.93 | MAPT (0.39) | PDE5AGRM2METAP2GABRG2GABRB3 | |
| SCHEMBL2661952 | 0.93 | PDE5A (0.40) | PDE5AGABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL2661947 | 0.90 | CRHR1 (0.46) | PDE5AGABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL2661405 | 0.88 | GABRG2 (0.42) | PDE5AGRM2METAP2GABRG2GABRB3 | |
| SCHEMBL2662436 | 0.88 | GABRG2 (0.49) | PDE5AGABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL2661488 | 0.88 | GRM2 (0.41) | GRM2GABRG2GABRB3GABRA2PDE4A | |
| SCHEMBL4923506 | 0.86 | PDE5A (0.37) | PDE5AGABRG2GABRB3GABRA2GABRA1 | |
| SCHEMBL4922967 | 0.85 | GABRG2 (0.39) | GABRG2GABRB3GABRA2GABRA1GABRA5 | |
| SCHEMBL2657124 | 0.85 | PDE5A (0.41) | PDE5AMETAP2GABRG2GABRB3GABRA2 | |
| SCHEMBL2655510 | 0.85 | PDE5A (0.41) | PDE5AMETAP2GABRG2GABRB3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | PDE5A 742/4885GRM2 316/4885METAP2 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.